Late reactivation of resolved hepatitis B virus infection: An increasing complication post rituximab‐based regimens treatment?

García-Rodríguez, María José; Canales, Miguel; Hernández‐Maraver, Dolores; Hernández-Navarro, Fernando

doi:10.1002/ajh.21214

Cited by 60 publications

(30 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition, it is not fully understood how long the pharmacological prophylaxis should last in order to prevent the reactivation of HBV infection. Observational studies suggest extending the prophylaxis to the 12 th month after the discontinuation of immunosuppressive treatment, but in some case reports HBV reactivation occurred later, especially in patients treated with rituximab [39,90] . Recently, Tonziello et al [39] described a reactivation of OBI in an HBsAgnegative/anti-HBc-positive woman with non-Hodgkin lymphoma occurring 20 mo after rituximab discontinuation despite lamivudine prophylaxis covering the 4 mo of rituximab administration and the 12 mo after its discontinuation.…”

Section: Infectionmentioning

confidence: 99%

Clinical impact of occult hepatitis B virus infection in immunosuppressed patients

Sagnelli

Pisaturo

Martini

et al. 2014

WJH

View full text Add to dashboard Cite

Section: Infectionmentioning

confidence: 99%

Clinical impact of occult hepatitis B virus infection in immunosuppressed patients

Sagnelli

Pisaturo

Martini

et al. 2014

WJH

View full text Add to dashboard Cite

“…The 2007 guidelines by Lok et al [50] are more specific than past guidelines and include a recommendation to extend the period of preventive lamivudine treatment, depending on HBV-DNA monitoring results. Some research reported a delayed onset of the HBV reactivation with rituximab therapy [69][70][71] . We also observed a case in which HBV reactivation was detected 4 years after chemotherapy and preventive lamivudine administration had been completed.…”

Section: Nucleoside Analog Treatment For the Prevention Of Hbv Reactimentioning

confidence: 99%

Hepatitis B virus reactivation with rituximab-containing regimen

Tsutsumi¹,

Yamamoto²,

Shimono³

et al. 2013

WJH

View full text Add to dashboard Cite

Rituximab is recognized as a useful drug for the treatment of B-cell non-Hodgkin's lymphoma and its use has been extended to such diseases as idiopathic thrombocytopenic purpura, thrombotic thrombocytopenic purpura, chronic rheumatoid arthritis and AN-CA-associated vasculitides. One serious complication associated with its use is the reactivation of hepatitis B virus and the search for methods to prevent this occurrence has resulted in the rapid accumulation of knowledge. In this review, we discuss case analyses from our department and other groups and outline the current knowledge on the topic and the remaining issues.© 2013 Baishideng Publishing Group Co., Limited. All rights reserved.Key words: Rituximab; Hepatitis B virus; Reactivation; Chemotherapy; Lamivudine; Non-Hodgkin's lymphoma Core tip: The deleterious effects of hepatitis B virus (HBV) reactivation in rituximab-containing chemotherapy regimens have been reported and the effect of lamivudine treatment in the prevention of HBV reactivation is also well documented. Once reactivated, HBV may lead to death due to hepatitis. In this review, we discuss the factors of preventive lamivudine treatment (especially in the course of HBV antibody), including to whom and for how long the drug should be given, based on case studies and reports that span rituximab's debut in 2002 on the Japanese market to June 2013.

show abstract

“…Actually, many cases of rituximab-associated hepatitis B have been reported. [15][16][17][18][19] When ROR of hepatitis B associated with each drug (Table 2) was compared with that in the absence of a concomitant drug, as shown in Table 3, no signal was detected in cyclophosphamide or vincristine, suggesting that drugs concomitantly administered in R-CHOP therapy, such as rituximab, increased the number of hepatitis B cases to the high rank. RORs of rituximab and prednisolone were higher than those of the other drugs in Table 3, suggesting that these drugs are more strongly associated with hepatitis B development than the other drugs.…”

Section: Discussionmentioning

confidence: 99%

Factorial Analysis of Hepatitis B Virus Reactivation-Induced Hepatitis B Using JADER

Hara

Matsumoto

Yokoyama

et al. 2017

Biological & Pharmaceutical Bulletin

View full text Add to dashboard Cite

Hepatitis B caused by chemotherapy-and immunosuppression-associated hepatitis B virus reactivation is likely to become fulminant, and a high mortality rate has been reported. In this study, using the Japanese adverse drug event report database (JADER), factorial analysis of patients who developed hepatitis B as an adverse event was performed. The number of reported cases of hepatitis B during the survey period was 781 and 185 of them (24%) died. Rituximab and prednisolone were administered to many cases (233, 216 cases, respectively), and the reporting odds ratios were high (65.35, 13.40, respectively), suggesting their strong association with the development of hepatitis B. Regarding the onset time, rituximab-induced hepatitis B developed within one year after administration in 83%, being a high frequency. Prednisolone-induced hepatitis B developed even after one year in 36%. Since prednisolone is used to treat rheumatoid arthritis at a dose ≤10 mg/d, the patients were divided based on the prednisolone dose into the groups treated at >10 and ≤10 mg/d, and the onset time was investigated in each group. The median onset time was 113 and 330 d, respectively, showing a significant difference. On time-to-event analysis using the Weibull distribution, rituximab was classified as the early failure type, and prednisolone and methotrexate for rheumatoid arthritis were classified as the wear out failure type. These findings are important information which may lead to early discovery of and taking actions against hepatitis B being helpful for providing appropriate medical care.

show abstract

Late reactivation of resolved hepatitis B virus infection: An increasing complication post rituximab‐based regimens treatment?

Cited by 60 publications

References 20 publications

Clinical impact of occult hepatitis B virus infection in immunosuppressed patients

Clinical impact of occult hepatitis B virus infection in immunosuppressed patients

Hepatitis B virus reactivation with rituximab-containing regimen

Factorial Analysis of Hepatitis B Virus Reactivation-Induced Hepatitis B Using JADER

Contact Info

Product

Resources

About